Bright Minds Biosciences (DRUG) AI Stock Analysis

• Market Cap: C$979.01M
• Dividend Yield: N/A
• Average Volume (3M): 451.00
• Price to Earnings (P/E): ―
• Beta (1Y): 24.74
• Revenue Growth: N/A
• EPS Growth: -43.64%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.97
• Shares Outstanding: 9,787,161
• 10 Day Avg. Volume: 620
• 30 Day Avg. Volume: 451
• PEG Ratio: -0.27
• Price to Book (P/B): 7.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -66.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$170.89
• Price Target Upside: 70.84% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -6.53
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$97.00 ▼(-3.03% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is primarily constrained by pre-revenue operations with sharply higher recent losses and ongoing cash burn, which dominate near-term financial performance. A very strong, low-debt balance sheet partially offsets these risks by improving funding flexibility. Technical indicators are mildly bearish and valuation metrics are weak due to negative earnings and no stated dividend yield.

Positive Factors

Very low debt / strong balance sheet

Extremely low leverage and a large equity base provide durable financial flexibility for a development-stage biotech. This reduces refinancing risk, supports continued R&D spending through clinical milestones, and lengthens runway versus peers reliant on debt financing.

Large assets provide funding cushion

Material asset backing increases optionality for non-dilutive partnerships, licensing, or staged financing and supports clinical programs during typical multi-quarter timelines. A strong asset base helps absorb operational shocks without urgent capital raises.

Focused, differentiated pipeline targeting serotonin subtypes

A clear scientific focus on selective serotonin receptor subtypes concentrates R&D resources and creates potential for differentiated assets in CNS disorders. This specialization can yield competitive advantages in partner interest, regulatory strategy, and future commercialization.

Negative Factors

Pre-revenue with sharply widening losses

The jump in operating losses signals heavier clinical and development spending that must be funded without product revenue. Persistent pre-revenue status makes the company dependent on external financing or partnerships, increasing dilution and execution risk.

Persistent negative operating and free cash flow

Sustained negative cash flow at this magnitude indicates ongoing cash burn tied to development programs. Unless offset by milestone funding or revenue, it will reduce runway and force capital raises that can dilute shareholders or shift strategic priorities away from long-term value creation.

Negative returns on equity and no revenue

Negative ROE combined with zero revenue highlights that the balance sheet cushion is not yet generating shareholder returns. Over the medium term, continued negative profitability increases pressure to demonstrate clinical progress or secure transformational partnerships to justify further investment.

Bright Minds Biosciences Business Overview & Revenue Model

Company Description

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

How the Company Makes Money

null

Bright Minds Biosciences Financial Statement Overview

Summary

Overall financials reflect a development-stage biotech: pre-revenue with materially widening losses (TTM net loss ~-$19.8M vs FY2024 ~-$2.8M) and persistent cash burn (TTM operating/free cash flow ~-$13.0M). The key offset is a strong, low-debt balance sheet (very low leverage), which supports near-term funding flexibility despite negative returns on equity.

Income Statement

The company is still pre-revenue (revenue is 0 across all periods), with consistently negative gross profit and recurring operating losses. Losses widened materially in TTM (Trailing-Twelve-Months) (net loss about -$19.8M) versus FY2024 (about -$2.8M), indicating a sharply higher cost base and weaker near-term earnings trajectory. A positive is that low financial leverage means losses are primarily operating-driven rather than interest-driven, but profitability remains a key weakness.

Balance Sheet

The balance sheet is a clear strength: debt is minimal (TTM total debt ~$0.10M) against a large equity base (~$89.3M), resulting in extremely low leverage (debt-to-equity ~0.002). Total assets are high (~$90.9M), providing financial flexibility, and low debt reduces refinancing risk. The main drawback is that equity returns are meaningfully negative (TTM return on equity around -20%) due to ongoing losses.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative (TTM operating and free cash flow about -$13.0M), reflecting ongoing cash burn. Free cash flow growth is volatile (TTM shows a positive growth rate, while FY2025 was slightly negative), which suggests spending levels can shift materially year to year. A modest positive is that cash burn broadly tracks reported losses (free cash flow to net income ~1), but the overall level of cash outflow remains a key risk until revenue ramps.

Breakdown	TTM	Sep 2025	Dec 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-55.34K	-76.87K	-73.36K	-72.45K	-6.04K	0.00
EBITDA	-19.14M	-13.86M	-2.72M	-7.28M	-14.73M	0.00
Net Income	-19.84M	-12.23M	-2.80M	-7.37M	-15.19M	-8.52M
Balance Sheet
Total Assets	90.88M	84.42M	6.10M	6.88M	12.09M	20.04M
Cash, Cash Equivalents and Short-Term Investments	89.05M	82.91M	5.72M	6.75M	11.63M	19.76M
Total Debt	104.90K	125.78K	118.96K	73.55K	139.91K	0.00
Total Liabilities	1.60M	2.38M	568.26K	280.86K	1.54M	638.57K
Stockholders Equity	89.28M	82.04M	5.54M	6.60M	10.54M	19.40M
Cash Flow
Free Cash Flow	-13.01M	-8.69M	-1.85M	-7.02M	-13.59M	-7.32M
Operating Cash Flow	-13.01M	-8.69M	-1.85M	-7.02M	-13.59M	-7.32M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	46.92M	85.57M	810.57K	2.19M	5.20M	26.06M

Bright Minds Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 100.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DRUG, the sentiment is Negative. The current price of 100.03 is below the 20-day moving average (MA) of 107.59, below the 50-day MA of 111.43, and above the 200-day MA of 79.64, indicating a neutral trend. The MACD of -3.31 indicates Positive momentum. The RSI at 42.98 is Neutral, neither overbought nor oversold. The STOCH value of 20.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DRUG.

Bright Minds Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-6.62	-107.76%	―	―	34.22%
DRUG	44 Neutral	C$979.01M	-28.32	-30.79%	―	―	-43.64%